A new case that could reach the Supreme Court will test generic-drug makers' liability over product labeling.. At issue is how quickly those companies need to match changes in labeling that are made by equivalent brand-name medicines. The case represents yet another contentious effort to interpret federal and state laws governing liability for medicines, a topic that has embroiled the pharmaceutical industry, regulators and the courts for the last several years.